SOLICITATION NOTICE
66 -- Fluidigm BioMark AX/MX real-time PCR System
- Notice Date
- 8/25/2010
- Notice Type
- Presolicitation
- NAICS
- 334516
— Analytical Laboratory Instrument Manufacturing
- Contracting Office
- Department of Health and Human Services, National Institutes of Health, National Cancer Institute, Office of Acquisitions, 6120 Executive Blvd., EPS Suite 600, Rockville, Maryland, 20852
- ZIP Code
- 20852
- Solicitation Number
- NCI-100206-TG
- Archive Date
- 9/24/2010
- Point of Contact
- Terry Galloway, Phone: 301-402-4509, Caren N Rasmussen, Phone: (301) 402-4509
- E-Mail Address
-
gallowaytl@mail.nih.gov, cr214i@nih.gov
(gallowaytl@mail.nih.gov, cr214i@nih.gov)
- Small Business Set-Aside
- N/A
- Description
- Contracting Office Address Department of Health and Human Services, National Institutes of Health, National Cancer Institute, Office of Acquisitions, 6120 Executive Blvd. EPS Room 6068, Rockville, MD, 20852, UNITED STATES Description The National Cancer Institute (NCI), Cancer Center Research (CCR), Molecular Diagnostics plans to procure on a sole source basis the brand name Fluidigm Biomark AX/MX real-time PCR system from Fluidigm Corporation, 7000 Shoreline Court, Suite 100, South San Francisco, CA 94080-1982. This acquisition will be processed under FAR Part 12 - Acquisition for Commercial Items and will be made pursuant to the authority in FAR 13.106-1(b)(2) and 13.501-(a)(1) using simplified acquisition procedures for commercial acquisitions. The North American Industry Classification System code is 334516 and the business size standard is 500 employees. Only one award will be made as a result of this solicitation. This will be awarded as a firm fixed price type contract. Delivery Date: 90 days from date of award. The Molecular Diagnostics Laboratory of the Laboratory of Pathology performs molecular testing to assist in the diagnosis of a variety of cancers. The laboratory develops gene-based tests that assist-in pathologic diagnosis, predict prognosis and identify potential targets for rational personalized therapies. It is currently the only CLIA and College of American Pathology approved clinical laboratory within the NCI certified for performing molecular oncology testing on materials from NIH patients. The Laboratory is developing Next Generation Sequencing approaches to provide a technology for enabling the rapid identification of cancer- specific prognostic genetic information and for identification of potential targets for therapy, through highly multiplexed genetic mutation screening. Facts and Reasons to Justify Other than Full and Open Competition: Statutory authority: This justification has been prepared under the authority of 41 U.S.C. 253 (c)(1) as set forth in 13.106-1 (b)(1). (b) Soliciting from a single source. (1) For purchases not exceeding the simplified acquisition threshold, contracting officers may solicit from one source if the contracting officer determines that the circumstances of the contract action deem only one source reasonably available (e.g., urgency, exclusive licensing agreements, or industrial mobilization). No other requirement and/or type for supply or service will satisfy agency need. Justification: The BioMark System. MX Package is a fully integrated system enabling of gene expression, genotyping, mutant detection, and absolute quantization nucleic-acid sequences utilizing Digital and/or Dynamic Array Integrated Fluidic (IFC) technology. Its unique access array capability enables the efficient Polymerase Chain Reaction (PCR) amplification and mechanical harvest of multiple amplicons across a large sample set to both enrich for regions of interest and maximize utility of next-generation sequencing. The following salient characteristics are unique or characteristic to the BioMark System MX Package: • Flexible and user configurable (e.g. non spotted) fluidic array technology • Performs more than 2300 pair-wise reactions_ parallel between 48 unique samples and 48 unique assays, or 9600 from 96 unique samples and 96 unique assays • Utilizes.fixed nanoliter volume reaction chambers which enable controlled reproducible results independent of input sample and assay volumes • Performs genetic analyses including gene expression with real time PCR reagents, genotyping (end point analysis), and digital Polymerase Chain Reaction (PCR) • Genetic analysis platform array with detection sensitivity of a single copy per chamber (reaction) • Absolute quantification of amplifiable DNA for Next Generation Sequencing libraries • Genotyping call rate of 99% or greater and call accuracy of 99.75% or greater. • Genetic analysis platform for use in gene expression with quantitative resolution of a 2-fold difference in starting copy with a 99.7% or greater confidence. • Efficient PCR amplification and mechanical harvest of 48 x 48 amplicons versus DNA templates to enrich for regions of interest from 2 ng or less genomic DNA • Absolute quantization of nucleic-acid sequences utilizing Digital, and/or Dynamic Array Integrated Fluidic (IFC) technology • Detects gene expression profiles from starting RNA material of less than 1 picogram. The system is solely produced by Fluidigm Corp. and the key components are patented and designed to operate as an integrated system. Therefore, no other source is known to the NCI to comply with the needs of the lab for this acquisition. This is not a solicitation for competitive quotations. However, if any interested party believes they can meet the above requirement, they may submit a statement of capabilities. All information furnished must be in writing and must contain sufficient detail to allow the NCI to determine if it can meet the above unique specifications described herein. An original and one copy of the capability statement must be received at the NCI Office of Acquisitions on or before 11:00 AM EST on September 9, 2010. No electronic capability statements will be accepted (i.e. email or fax), an original and one copy must be sent to the NCI Office of Acquisitions to the address stated above. All questions must be in writing and can be faxed (301) 402-4513 or emailed to Terry Galloway, Contract Specialist at gallowaytl@mail.nih.gov. A determination by the Government not to compete this proposed contract based upon responses to this notice is solely within the discretion of the Government. Information received will be considered solely for the purpose of determining whether to conduct a competitive procurement. In order to receive an award, contractors must have valid registration and certification in the Central Contractor Registration (CCR) www.ccr.gov and the Online Representations and Certifications Applications (ORCA), http://orca.bpn.gov. No collect calls will be accepted. Please reference solicitation number NCI-100206-TG on all correspondences.
- Web Link
-
FBO.gov Permalink
(https://www.fbo.gov/spg/HHS/NIH/RCB/NCI-100206-TG/listing.html)
- Record
- SN02254854-W 20100827/100825235741-631d3b1924443452e0d133baa1d5d7ad (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |